Build the Simulation
Cross-site searchCtrl / ⌘ + K
BCI Atlas Company brief Europe

CorTec

CorTec’s Brain Interchange: a fully implantable, wireless, closed-loop neurotechnology platform moving into first-in-human use in Europe.

CorTec (Germany) is developing the Brain Interchange System, a platform positioned for implantable, wireless, closed-loop neurotechnology research and (eventually) therapies.

What they’re building

CorTec describes Brain Interchange as a system for pre-clinical and clinical research to develop therapies for neurological diseases.

  • CorTec site (Brain Interchange mention): 01
  • Stroke study details (Oct 9, 2026, Badische Zeitung interview): In an interview with Badische Zeitung, CorTec co-founder Martin Schüttler said that in the company’s studies stroke patients steered the computer game Pong by thought alone, and that targeted stimulation supported the relearning of movements. He described the system’s electronics as sitting between skull and scalp, with silicone contact mats placed directly on the brain. Regional-press interview, not peer reviewed. Source: 02

First-in-human milestone (reported)

BioWorld reported that CorTec implanted its Brain Interchange BCI system into a stroke patient in late July 2025.

  • BioWorld (Jul 30, 2025): 03
  • FDA designations: CorTec announced a second FDA Breakthrough Device Designation for Brain Interchange (Aug 31, 2026). Source: 04
  • Clinical: Brain Interchange is described as the first European implantable BCI with an FDA-approved (IDE) US trial; lead indication is stroke rehabilitation. Source: 05 A University of Washington lab reported cursor control by its first participant in Apr 2026: 06

Why it matters

A lot of BCI discourse is dominated by “assistive” use cases (cursor control, typing). CorTec sits closer to the therapeutic / closed-loop lane, where the key engineering questions are:

  • stable long-term recording
  • safe stimulation
  • telemetry / power
  • clinical reliability and workflow

What to watch

  1. Indications and trial design What is the first target (stroke rehab, epilepsy, movement disorders, etc.) and what are the endpoints?

  2. Closed-loop performance How are biomarkers defined, detected, and used to control stimulation in real time?

  3. Device practicality Implant size, longevity, recharge strategy, reliability, and surgical burden.

Source index

References, research and company reports.

  1. cortec-neuro.com Reference

    CorTec site (Brain Interchange mention)
    Back to section

  2. badische-zeitung.de Reference

    Freiburger start up cortec testet hirnimplantat bei schlaganfallpatienten
    Back to section

  3. bioworld.com Reference

    BioWorld (Jul 30, 2025)
    Back to section

  4. cortec-neuro.com Reference

    FDA designations: CorTec announced a second FDA Breakthrough Device Designation for Brain Interchange (Aug 31, 2026). Source
    Back to section

  5. brain-interchange.com Reference

    Official website
    Back to section

  6. sites.uw.edu Reference

    New demonstration of cortical brain computer interface control of a cursor using the cortec brain interchange device
    Back to section